Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1963 3
1964 2
1965 2
1966 1
1967 1
1968 1
1969 3
1970 3
1971 2
1972 1
1973 1
1974 1
1980 1
1981 2
1986 1
1987 1
1988 1
1989 5
1991 2
1992 2
1993 2
1994 1
1995 4
1996 2
1997 5
1998 9
1999 14
2000 9
2001 8
2002 14
2003 19
2004 5
2005 15
2006 14
2007 13
2008 23
2009 29
2010 51
2011 51
2012 45
2013 32
2014 35
2015 46
2016 43
2017 61
2018 57
2019 64
2020 61
2021 74
2022 45
2023 56
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

855 results

Results by year

Filters applied: . Clear all
Page 1
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Liu E, et al. Among authors: marin d. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. Li Y, et al. Among authors: marin d. Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29. Nat Med. 2022. PMID: 36175679 Free PMC article.
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Liu E, et al. Among authors: marin d. Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20. Leukemia. 2018. PMID: 28725044 Free PMC article.
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.
Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Shaim H, et al. Among authors: marin d. J Clin Invest. 2021 Jul 15;131(14):e142116. doi: 10.1172/JCI142116. J Clin Invest. 2021. PMID: 34138753 Free PMC article.
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Daher M, et al. Among authors: marin d. Blood. 2021 Feb 4;137(5):624-636. doi: 10.1182/blood.2020007748. Blood. 2021. PMID: 32902645 Free PMC article.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Gaballa MR, et al. Among authors: marin d. Blood. 2022 Mar 24;139(12):1908-1919. doi: 10.1182/blood.2021013290. Blood. 2022. PMID: 34914826 Free PMC article.
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Jabbour E, et al. Among authors: marin d. JAMA Oncol. 2018 Feb 1;4(2):230-234. doi: 10.1001/jamaoncol.2017.2380. JAMA Oncol. 2018. PMID: 28859185 Free PMC article. Clinical Trial.
Zearalenone and the Immune Response.
Bulgaru CV, Marin DE, Pistol GC, Taranu I. Bulgaru CV, et al. Among authors: marin de. Toxins (Basel). 2021 Mar 31;13(4):248. doi: 10.3390/toxins13040248. Toxins (Basel). 2021. PMID: 33807171 Free PMC article. Review.
855 results